Hydrochlorothiazide
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Hydrochlorothiazide |
| DrugBank ID | DB00999 |
| Brand Names (EU) | Hydrochlorothiazide, Tolucombi |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 98.42% |
Approved Indication (EMA)
Treatment of essential hypertension. PritorPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone. PritorPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on PritorPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients w
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | malignant hypertensive renal disease | 98.42% | DL |
| 2 | malignant renovascular hypertension | 98.42% | DL |
| 3 | pulmonary hypertension owing to lung disease and/or hypoxia | 98.35% | DL |
| 4 | pulmonary hypertension with unclear multifactorial mechanism | 98.35% | DL |
| 5 | hypertensive disorder | 98.28% | DL |
| 6 | Braddock syndrome | 97.92% | DL |
| 7 | chronic pulmonary heart disease | 97.80% | DL |
| 8 | congestive heart failure | 93.70% | DL |
| 9 | acute pulmonary heart disease | 93.17% | DL |
| 10 | primary hereditary glaucoma | 90.87% | DL |
| 11 | open-angle glaucoma | 86.16% | DL |
| 12 | hypotrichosis simplex of the scalp | 74.54% | DL |
| 13 | congenital hypotrichosis milia | 72.80% | DL |
| 14 | distal myopathy, Tateyama type | 70.46% | DL |
| 15 | chronic kidney disease | 69.85% | DL |
| 16 | hypertrophic cardiomyopathy due to intensive athletic training | 67.51% | DL |
| 17 | hypertrophic cardiomyopathy | 66.83% | DL |
| 18 | end stage renal failure | 65.88% | DL |
| 19 | cirrhotic cardiomyopathy | 65.18% | DL |
| 20 | diffuse alopecia areata | 65.03% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.